BamSEC and AlphaSense Join Forces
Learn More

Athira Pharma Inc.

NASDAQ: ATHA    
Share price (12/20/24): $0.58    
Market cap (12/20/24): $22.3 million

Material Contracts Filter

EX-10.2
from 8-K 30 pages October 1, 2024 * * *
12/34/56
EX-10.1
from 8-K 16 pages *Certain Portions of This Exhibit Have Been Omitted Because They Are Not Material and Is the Type of Information That the Company Treats as Private or Confidential
12/34/56
EX-10.2
from 8-K 11 pages Athira Pharma, Inc. Change in Control Agreement
12/34/56
EX-10.1
from 8-K 5 pages Material contract
12/34/56
EX-10.2
from 10-Q/A 13 pages Athira Pharma, Inc. Change in Control and Severance Agreement
12/34/56
EX-10.1
from 10-Q/A 4 pages Material contract
12/34/56
EX-10.1
from 8-K 47 pages Athira Pharma, Inc. 2024 Inducement Equity Incentive Plan 1. Purposes of the Plan. the Purposes of This Plan Are to Attract and Retain the Best Available Personnel for Positions of Substantial Responsibility by Providing an Inducement Material to Individuals Entering Into Employment With the Company or Any Parent or Subsidiary of the Company
12/34/56
EX-10.1
from 8-K 22 pages Executive Transition Agreement
12/34/56
EX-10.3
from 8-K 29 pages Transition Agreement and Release
12/34/56
EX-10.2
from 8-K 12 pages Athira Pharma, Inc. Change in Control and Severance Agreement
12/34/56
EX-10.1
from 8-K 5 pages May 18, 2023 Andrew Gengos [Address] [Email] Dear Andrew: We Are Pleased to Offer You a Position With Athira Pharma, Inc. (The “Company”). if You Decide to Join US, You Will Become Part of a Fast-Paced and Dedicated Team That Works Together to Accelerate the Development of Life Changing Therapeutics
12/34/56
EX-10
from 10-K 6 pages Athira Pharma, Inc. Outside Director Compensation Policy as Amended January 27, 2023
12/34/56
EX-10
from 10-K 26 pages Purpose. the Purpose of the Plan Is to Provide Employees of the Company and Its Designated Companies With an Opportunity to Purchase Common Stock Through Accumulated Contributions. the Company Intends for the Plan to Have Two Components: A Component That Is Intended to Qualify as an “Employee Stock Purchase Plan” Under Code Section 423 (The “423 Component”) and a Component That Is Not Intended to Qualify as an “Employee Stock Purchase Plan” Under Code Section 423 (The “Non‑423 Component”). the Provisions of the 423 Component, Accordingly, Will Be Construed So as to Extend and Limit Plan Participation in a Uniform and Nondiscriminatory Basis Consistent With the Requirements of Code Section 423. in Addition, This Plan Authorizes the Grant of an Option to Purchase Shares of Common Stock Under the Non‑423 Component That Does Not Qualify as an “Employee Stock Purchase Plan” Under Code Section 423; an Option Granted Under the Non‑423 Component Will Provide for Substantially the Same Benefits as an Option Granted Under the 423 Component, Except That a Non‑423 Component Option May Include Features Necessary to Comply With Applicable NON‑U.S. Laws Pursuant to Rules, Procedures or Sub‑plans Adopted by the Administrator. Except as Otherwise Provided Herein or by the Administrator, the Non‑423 Component Will Operate and Be Administered in the Same Manner as the 423 Component. 2. Definitions. 2.1 “Administrator” Means the Board or Any Committee Designated by the Board to Administer the Plan Pursuant to Section 3. 2.2
12/34/56
EX-10.28
from 10-K 13 pages Athira Pharma, Inc. Change in Control and Severance Agreement
12/34/56
EX-10.27
from 10-K 3 pages November 17, 2021 Hans Moebius, M.D., Ph. D. via Email Re: Amendment to Employment Agreement Dear Hans
12/34/56
EX-10.2
from 8-K 5 pages Athira Pharma, Inc. Outside Director Compensation Policy as Amended January 27, 2022
12/34/56
EX-10.1
from 8-K 13 pages Athira Pharma, Inc. Amended and Restated Change in Control and Severance Agreement
12/34/56
EX-10.1
from 8-K 11 pages Separation Agreement and Release
12/34/56
EX-10.5
from 10-Q 5 pages First Amendment to Lease
12/34/56
EX-10.4
from 10-Q 12 pages Athira Pharma, Inc. Change in Control and Severance Agreement
12/34/56